Personalized Pharmaceutical Systems

Personalized Pharmaceutical Systems (PPS) is a cutting edge clinical trial enrichment and market differentiation company that has developed an advanced technology designed to dramatically reduce the risks associated with drug development and post-market entry phases, with a particular focus in CNS and Immunology disorders. PPS views inter-individual variability in drug response as an aid, rather than a confounder in drug development and marketing. Our novel enrichment technology works within heterogeneous patient populations to delineate meaningful subgroups according to similarly responding phenotypes, and create simple and standardized clinical tools to quickly and accurately identify the target population for a specific treatment whether already used in clinical practice or under experimental development. Through identification of specific phenotypes and the refinement of disease diagnostic types, PPS technology can efficiently remove the percentage of subjects who are unresponsive to or adversely affected by a treatment under study. PPS technology can shift compounds from potentially being shelved in Phase to clearly demonstrating efficacy and safety to achieve FDA approval. Enrichment criteria based on true phenotype differences can likewise differentiate a drug therapy in the market through Clinical Predictive Tools (CPTs) leading to concise and clear “drug of choice” indications for currently underutilized or undifferentiated treatments. Our company is driven by a “hands on” approach to all project management and brings substantial experience in evaluating and developing diagnostic tools core to our technology. Our team is efficient, highly responsive, quickly scalable and able to execute multiple studies simultaneously.